SCHEMBL30865235

SCHEMBL30865235

O=C(N1CC2(CC(n3cnc(C4CC4)n3)C2)C1)N1CC2(CN(Cc3ncc(C(F)F)s3)C2)C1

nearest known ligand 0.53

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 6/20 0.53
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ IDO1 P14902 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30865452 0.92 MGLL (0.51) MGLLCYP3A4CYP2D6
SCHEMBL30865441 0.87 MGLL (0.45) MGLL
SCHEMBL30865338 0.86 MGLL (0.39) MGLL
SCHEMBL30865432 0.86 MGLL (0.60) MGLLCYP3A4CYP2D6IDO1
SCHEMBL30865310 0.85 MGLL (0.51) MGLLCYP3A4CYP2D6IDO1
SCHEMBL30865322 0.82 MGLL (0.53) MGLLCYP3A4CYP2D6IDO1
SCHEMBL30865220 0.82 MGLL (0.57) MGLL
SCHEMBL25322759 0.80 MGLL (0.36) MGLL
SCHEMBL30865343 0.80 MGLL (0.59) MGLLCYP3A4
SCHEMBL30865156 0.80 MGLL (0.53) MGLLCYP3A4CYP2D6IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608823-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) F. Hoffmann-La Roche AG (CH) 2025-09-03 — — EP claimed
WO-2024088922-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) F. HOFFMANN-LA ROCHE AG (CH) 2024-05-02 — — WO claimed
EP-4608823-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) F. Hoffmann-La Roche AG (CH) 2025-09-03 — — EP disclosed
WO-2024088922-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) F. HOFFMANN-LA ROCHE AG (CH) 2024-05-02 — — WO disclosed
Send feedback